D. E. Shaw & Co. Inc. Sells 407,076 Shares of Biohaven Ltd. (NYSE:BHVN)

D. E. Shaw & Co. Inc. reduced its position in Biohaven Ltd. (NYSE:BHVN - Free Report) by 70.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 170,647 shares of the company's stock after selling 407,076 shares during the period. D. E. Shaw & Co. Inc. owned about 0.17% of Biohaven worth $6,374,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BHVN. JPMorgan Chase & Co. increased its stake in shares of Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after purchasing an additional 1,169,721 shares during the last quarter. Norges Bank acquired a new position in shares of Biohaven during the 4th quarter worth $33,711,000. Vanguard Group Inc. increased its stake in shares of Biohaven by 8.1% during the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock worth $314,267,000 after purchasing an additional 628,211 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Biohaven by 160.7% during the 4th quarter. Wellington Management Group LLP now owns 634,055 shares of the company's stock valued at $23,682,000 after acquiring an additional 390,888 shares during the last quarter. Finally, Boone Capital Management LLC acquired a new position in shares of Biohaven during the 4th quarter valued at about $13,499,000. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Stock Up 3.0%

NYSE BHVN traded up $0.47 during trading hours on Tuesday, hitting $16.22. The company's stock had a trading volume of 2,291,251 shares, compared to its average volume of 1,221,265. The stock has a fifty day moving average of $22.03 and a 200 day moving average of $33.85. Biohaven Ltd. has a twelve month low of $14.69 and a twelve month high of $55.70. The firm has a market capitalization of $1.66 billion, a P/E ratio of -1.73 and a beta of 1.18.

Biohaven (NYSE:BHVN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current year.

Insider Buying and Selling at Biohaven

In other news, Director John W. Childs bought 32,700 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 16.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BHVN shares. William Blair raised shares of Biohaven to a "strong-buy" rating in a research report on Thursday, April 24th. Robert W. Baird decreased their price target on Biohaven from $60.00 to $57.00 and set an "outperform" rating on the stock in a research note on Monday, April 28th. JPMorgan Chase & Co. reduced their price target on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 price target on shares of Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $59.46.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.